Moonlake Immunotherapeutics (MLTX) Stock Price, Quote & News

Company Profile

MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Industry: Biotechnology

Sector: Healthcare

Phone: 41 415108022

Website: www.moonlaketx.com

Address:

Dorfstrasse 29, Zug, Switzerland

Doozio Jul. 4 at 5:13 PM

Out of 🐑⏰♾️ MAMA said da cup n handle BROS where going biotech $MLTX by da summer lake during 🐒🍌🧠⏰♾️

1 · Reply

bigkahunatrader Jul. 2 at 6:14 AM

$MLTX Moonlake Imunotherapeutics, Inc. TM-5 Cycle Trade...Stock Rating 83 https://youtu.be/miGmVtMT7RY

0 · Reply

penelope6 Jun. 24 at 12:27 PM

$MLTX someone knocking at the door, let them in

0 · Reply

penelope6 Jun. 18 at 4:11 PM

$MLTX up like this with light volume??? suspect.

0 · Reply

swingingtech Jun. 18 at 1:54 PM

$ESML $MLTX $RXST $RBBN https://wallstreetwaves.com/projected-growth-esml-could-reach-48/

0 · Reply

Whiskeyunderthebed Jun. 10 at 7:31 PM

$MLTX expect $60 a share.

1 · Reply

OpenOutcrier Jun. 9 at 11:42 AM

$MLTX (+0.0% pre) StockWatch: Report of $3B+ $MRK Merck Buyout Offer Propels MoonLake Stock Surge https://ooc.bz/l/67292

0 · Reply

BigSqueezeComing Jun. 9 at 1:06 AM

$MLTX bid implied a roughly 15–20% premium per share

0 · Reply

BigSqueezeComing Jun. 9 at 1:03 AM

$MLTX Jan–May 202---Merck submitted a non-binding >$3B offer for MLTX

1 · Reply

YasirTrades Jun. 8 at 8:29 PM

GLMD setup looks like $ONC (+40%), $KYMR (+50%), $MLTX (+16% on takeover buzz), and $BPMC (+26% on $9B buyout). GLMD still under $1.40, $12+ book, low float, no dilution. Chart’s coiled. One spark and this can rip. GLMD #biotech #smallcaps #squeeze

0 · Reply

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest

Jun 2, 2025, 5:08 PM EDT - 4 weeks ago

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports

MRK

May 12, 2025, 4:00 PM EDT - 7 weeks ago

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

Apr 25, 2025, 4:05 PM EDT - 2 months ago

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

Apr 8, 2025, 3:31 AM EDT - 3 months ago

MoonLake Immunotherapeutics: A Buy At Dips

Apr 3, 2025, 7:00 AM EDT - 3 months ago

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

Feb 26, 2025, 7:00 AM EST - 4 months ago

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Jan 17, 2025, 6:03 PM EST - 6 months ago

MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon

Jan 8, 2025, 7:00 AM EST - 6 months ago

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

Sep 9, 2024, 7:00 AM EDT - 10 months ago

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

Jul 18, 2024, 2:19 PM EDT - 1 year ago

MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

May 16, 2024, 8:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

May 12, 2024, 8:37 AM EDT - 1 year ago

MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion

May 7, 2024, 8:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

Apr 10, 2024, 7:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

Apr 10, 2024, 7:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

Mar 10, 2024, 12:00 PM EDT - 1 year ago

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

Mar 4, 2024, 8:00 AM EST - 1 year ago

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

Feb 29, 2024, 8:00 AM EST - 1 year ago

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

Feb 26, 2024, 8:00 AM EST - 1 year ago

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

Dec 9, 2023, 6:38 AM EST - 1 year ago

MoonLake Immunotherapeutics Is A Promising Bet On Psoriasis Treatment

Nov 14, 2023, 8:00 AM EST - 1 year ago

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Nov 5, 2023, 11:00 AM EST - 1 year ago

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

Oct 15, 2023, 9:03 AM EDT - 1 year ago

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

Oct 11, 2023, 10:15 AM EDT - 1 year ago

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress

Oct 4, 2023, 7:01 AM EDT - 1 year ago

Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress

Sep 27, 2023, 8:00 PM EDT - 1 year ago

MoonLake Immunotherapeutics Is Now Thoroughly De-Risked

Sep 6, 2023, 7:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

Aug 27, 2023, 11:54 PM EDT - 2 years ago

Anchored In Innovation: MoonLake Immunotherapeutics Charts A New Course (Rating Upgrade)

Aug 10, 2023, 7:00 AM EDT - 2 years ago

MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

Jul 31, 2023, 2:43 PM EDT - 2 years ago

August MDA Breakout Stocks Week 31 - 2023: High-Frequency Gainers To Give You An Edge

AAPL AMGN ARDX CELH COIN CSCO CVX

Jul 25, 2023, 8:00 AM EDT - 2 years ago

MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts

Jul 24, 2023, 2:45 PM EDT - 2 years ago

Strong Mid-Cap Insider Buys: Q2 2023

ABCB ADC CLF CNX DISH EWBC GME

Jul 14, 2023, 3:38 PM EDT - 2 years ago

Exclusive: MoonLake Immunotherapeutics explores sale-sources

Jun 28, 2023, 5:00 AM EDT - 2 years ago

MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares

Jun 27, 2023, 5:50 PM EDT - 2 years ago

MoonLake: Further Gains Possible With End Of 2023 Data Releases

Jun 26, 2023, 4:01 PM EDT - 2 years ago

MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering

Jun 25, 2023, 9:00 AM EDT - 2 years ago

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

May 12, 2023, 7:45 AM EDT - 2 years ago

MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

May 3, 2023, 6:45 AM EDT - 2 years ago

MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply

Apr 27, 2023, 9:30 AM EDT - 2 years ago

MoonLake Immunotherapeutics: Cosentyx Rival With Numerically Better Data

Apr 19, 2023, 8:16 AM EDT - 2 years ago

MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today

Mar 20, 2023, 7:45 AM EDT - 2 years ago

MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update

Feb 2, 2023, 8:00 AM EST - 2 years ago

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa

Dec 14, 2022, 8:00 AM EST - 2 years ago

MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis

Nov 14, 2022, 8:00 AM EST - 2 years ago

MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update

Sep 26, 2022, 8:00 AM EDT - 3 years ago

MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis

Jul 26, 2022, 8:00 AM EDT - 3 years ago

MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH

Jul 21, 2022, 1:15 PM EDT - 3 years ago

HC Wainwright Starts Coverage On This 'Best-In-Class Agent For Inflammatory Disorders

May 31, 2022, 9:24 AM EDT - 3 years ago

Why MoonLake Immunotherapeutics Shares Are Surging Higher Today

Doozio Jul. 4 at 5:13 PM

Out of 🐑⏰♾️ MAMA said da cup n handle BROS where going biotech $MLTX by da summer lake during 🐒🍌🧠⏰♾️

1 · Reply

bigkahunatrader Jul. 2 at 6:14 AM

$MLTX Moonlake Imunotherapeutics, Inc. TM-5 Cycle Trade...Stock Rating 83 https://youtu.be/miGmVtMT7RY

0 · Reply

penelope6 Jun. 24 at 12:27 PM

$MLTX someone knocking at the door, let them in

0 · Reply

penelope6 Jun. 18 at 4:11 PM

$MLTX up like this with light volume??? suspect.

0 · Reply

swingingtech Jun. 18 at 1:54 PM

$ESML $MLTX $RXST $RBBN https://wallstreetwaves.com/projected-growth-esml-could-reach-48/

0 · Reply

Whiskeyunderthebed Jun. 10 at 7:31 PM

$MLTX expect $60 a share.

1 · Reply

OpenOutcrier Jun. 9 at 11:42 AM

$MLTX (+0.0% pre) StockWatch: Report of $3B+ $MRK Merck Buyout Offer Propels MoonLake Stock Surge https://ooc.bz/l/67292

0 · Reply

BigSqueezeComing Jun. 9 at 1:06 AM

$MLTX bid implied a roughly 15–20% premium per share

0 · Reply

BigSqueezeComing Jun. 9 at 1:03 AM

$MLTX Jan–May 202---Merck submitted a non-binding >$3B offer for MLTX

1 · Reply

YasirTrades Jun. 8 at 8:29 PM

0 · Reply

YasirTrades Jun. 8 at 8:25 PM

GLMD setup reminds me of $KYMR (+41% on trial data), $MLTX (+20% on takeover buzz), $BPMC (+26% on $9B buyout), and $CRBU (+13% on volume/trial updates). $ is under $1.40 with $12+ book, low float, no dilution. Just needs a catalyst. GLMD #biotech #smallcaps

0 · Reply

OpenOutcrier Jun. 5 at 12:56 PM

$MLTX (-2.1% pre) MoonLake Immunotherapeutics is for sale? This sounds like a cry for help - STAT https://ooc.bz/l/66996

0 · Reply

ZacksResearch Jun. 4 at 6:09 PM

$MLTX surges 18% on Merck acquisition rumors! Merck reportedly made a $3B+ non-binding offer for MoonLake earlier this year. Talks could reignite, with other suitors possibly in the mix. Find out what this means for the stock and the biotech space 👉 https://www.zacks.com/commentary/2484733/mltx-stock-gains-18-as-merck-reportedly-eyes-buyout?cid=sm-stocktwits-2-2484733-body&ADID=SYND_STOCKTWITS_TWEET_2_2484733_BODY

0 · Reply

Jbiv1971 Jun. 4 at 4:49 PM

$MLTX What does a 3.50B buyout look like for the share price?

1 · Reply

ZacksResearch Jun. 4 at 4:43 PM

$MLTX up 18% on fresh buyout buzz — is Merck ready to strike? A report says $MRK made a $3B+ offer earlier this year, and talks could be back on the table. M&A watch heating up 👀 Full scoop here 👉 https://www.zacks.com/stock/news/2484733/mltx-stock-gains-18-as-merck-reportedly-eyes-buyout?cid=sm-stocktwits-2-2484733-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2484733_TEASER

0 · Reply